Lord, Abbett & Co. LLC Revance Therapeutics, Inc. Transaction History

Lord, Abbett & Co. LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Oct 07, 2024	BUY	$24.7 - $37.61 $25.1 Million - $38.2 Million	1,016,810 Added 438.7%	1,248,586 $31.6 Million
Q2 2023 Aug 14, 2023	BUY	$24.7 - $37.61 $25.1 Million - $38.2 Million	1,016,810 Added 438.7%	1,248,586 $31.6 Million
Q1 2023 Oct 07, 2024	BUY	$18.36 - $35.27 $4.26 Million - $8.17 Million	231,776 New	231,776 $7.47 Million
Q1 2023 May 12, 2023	BUY	$18.36 - $35.27 $4.26 Million - $8.17 Million	231,776 New	231,776 $7.47 Million

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.